Alisertib

Douglas M. Hunt sold 8,633 Puma Biotechnology shares at $3.1517, totaling $27,208, retaining 124,594 shares. Puma's Q3 2024 revenue hit $80.5M, driven by NERLYNX sales and Chinese market royalties. NCCN endorsed Nerlynx for cervical cancer treatment. Analysts maintain a 'Buy' rating, with Nerlynx sales projected at $187.2M for 2024.

Alan H. Auerbach, CEO of Puma Biotechnology, sold 33,841 shares at $3.1517 each, totaling $106,656, retaining 7,029,674 shares. Puma's Nerlynx endorsed by NCCN for cervical cancer treatment, boosting its profile. Q3 2024 revenue hit $80.5M, driven by Nerlynx sales and Chinese market royalties, with full-year revenue forecasted between $187M and $290M.

Puma Biotechnology granted 24,375 shares to two new employees under its 2017 plan, vesting over three years. Focused on cancer care, Puma markets NERLYNX® and is developing alisertib for lung and breast cancer treatments.

Puma Biotechnology announced NCCN updated cervical cancer guidelines to include neratinib monotherapy for HER2-mutated tumors, based on Phase II SUMMIT trial results.

Puma Biotechnology announced NCCN updated cervical cancer guidelines to include neratinib monotherapy for HER2-mutated tumors, based on Phase II SUMMIT trial results. This addition aims to improve treatment options for recurrent or metastatic disease.

Puma Biotechnology announced NCCN updated cervical cancer guidelines to include neratinib for HER2-mutated tumors. This addition is based on the Phase II SUMMIT trial results, offering neratinib as a second-line therapy option for patients with HER2-mutated recurrent or metastatic cervical cancer.

Puma Biotechnology announced NCCN updated cervical cancer guidelines to include neratinib monotherapy for HER2-mutated tumors, based on Phase II SUMMIT trial results.